PhotoPharmics

Executive Summary

PhotoPharmics is a clinical-stage biotechnology company developing a novel, non-pharmacological phototherapy device for Parkinson’s disease (PD). With over 11 million people affected worldwide and limited treatment advances in decades, the company’s approach targets mitochondrial dysfunction and circadian rhythm disruption—key drivers of PD progression. Unlike drug-based therapies, PhotoPharmics’ device delivers specific wavelengths of light to stimulate cellular energy production and restore sleep-wake cycles, potentially slowing disease progression while avoiding systemic side effects. The company has advanced its lead candidate to Phase 3 clinical trials, positioning it for a potential breakthrough in a market with high unmet need. Positive Phase 2 results demonstrated clinically meaningful improvements in motor and non-motor symptoms. If successful, PhotoPharmics could become the first disease-modifying therapy for PD without pharmacological risks. The market opportunity is substantial given the growing PD population and demand for safer, adjunctive treatments. However, regulatory and reimbursement hurdles remain for novel device-based therapies.

Upcoming Catalysts (preview)

• Q1 2027Phase 3 Topline Data Readout55% success
• Q3 2026FDA Breakthrough Device Designation40% success
• Q4 2026Strategic Partnership for Commercialization50% success